BG Medicine (BGMD) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
BG Medicine Reports Third Quarter 2014 Financial Results
November 13, 2014 6:30 AM ESTNet Loss Reduced by 35% and Operating Cash Burn Cut by 48% From Third Quarter 2013
Company Retains Investment Bank to Explore Strategic Alternatives
WALTHAM, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- BGMedicine, Inc. (Nasdaq: BGMD), the developer of the BGM Galectin-3®Test, today reported financial results for the third quarter... More



